Literature DB >> 23917526

Targeted therapies: HERA update-1 year is standard.

Lisa Hutchinson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23917526     DOI: 10.1038/nrclinonc.2013.145

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

Authors:  Aron Goldhirsch; Richard D Gelber; Martine J Piccart-Gebhart; Evandro de Azambuja; Marion Procter; Thomas M Suter; Christian Jackisch; David Cameron; Harald A Weber; Dominik Heinzmann; Lissandra Dal Lago; Eleanor McFadden; Mitch Dowsett; Michael Untch; Luca Gianni; Richard Bell; Claus-Henning Köhne; Anita Vindevoghel; Michael Andersson; A Murray Brunt; Douglas Otero-Reyes; Santai Song; Ian Smith; Brian Leyland-Jones; Jose Baselga
Journal:  Lancet       Date:  2013-07-18       Impact factor: 79.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.